List view / Grid view
9 October 2015 | By Victoria White
#CPhIChat is an industry-wide Tweetchat for pharma professionals working across the supply chain, aimed to stimulate conversations on key industry issues...
9 October 2015 | By Victoria White
This new recommendation for Keytruda is for treating advanced melanoma that has not been previously treated with ipilimumab...
9 October 2015 | By Victoria White
Verastem’s announcement comes just weeks after the company had to abandon enrolment in a Phase 2 study of its lead cancer drug VS-6063...
9 October 2015 | By Victoria White
The study demonstrate that eltrombopag is well tolerated and effective, consistently stabilising the platelet count to over 50 X 109 per litre within 2-6 weeks for 40% of children...
9 October 2015 | By Victoria White
Roche’s Chief Medical Officer said the results of the pivotal trials have the potential to transform the treatment of MS...
8 October 2015 | By Victoria White
Boehringer Ingelheim has reported new results from a Phase II head-to-head psoriasis study that showed superior efficacy of the company’s biologic compound BI 655066 over ustekinumab...
8 October 2015 | By Victoria White
The designation relates to the clinical development programme for avelumab in metastatic MCC, which includes the Phase II study, JAVELIN Merkel 200...
8 October 2015 | By Victoria White
The FDA has granted Breakthrough Therapy Designation to abemaciclib for patients with refractory HR+ advanced or metastatic breast cancer...
8 October 2015 | By Victoria White
Lemtrada targets CD52, a protein abundant on T and B cells. Circulating T and B cells are thought to be responsible for the damaging inflammatory process in MS...
8 October 2015 | By Victoria White
The exclusivity ensures that the FDA will not approve any applications for biosimilars of the drug before July 2026...
8 October 2015 | By Victoria White
The analysis evaluated the proportion of Gilenya patients achieving 'no evidence of disease activity' (NEDA-4) every year over seven years...
7 October 2015 | By
Pembrolizumab was the first drug to be approved through the Medicines and Healthcare Products Regulatory Agency’s Early Access to Medicine Scheme (EAMS)...
7 October 2015 | By Victoria White
The value of the multiple sclerosis therapeutics market will rise slowly from $17.2 billion in 2014 to approximately $20 billion by 2024...
7 October 2015 | By Victoria White
Biogen is to present the data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)...
7 October 2015 | By Victoria White
Aristada is the first atypical antipsychotic with once-monthly and six-week dosing options for delivering and maintaining therapeutic levels of medication in the body through an injection...
